Medindia LOGIN REGISTER
Medindia
Advertisement

Access Pharmaceuticals Cobraxane Program Displays Significant Advantage Over Commercially-Available Paclitaxel Protein-Bound Particles

Wednesday, May 11, 2011 General News
Advertisement
Comparative Studies From Company's CobaCyte Tumor-Targeting Technology Program, Cobraxane, Demonstrate Superior Tumor Growth Inhibition

Contact: Company

Contact: Investor Relations

Christine Berni

Donald C. Weinberger/Diana Bittner (media)

Director of Investor Relations

Wolfe Axelrod Weinberger Assoc. LLC

Access Pharmaceuticals, Inc.

(212) 370-4500

(212) 786-6208

Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close